Abstract Background
There is growing interest in the use of routinely collected electronic health records to enhance service delivery and facilitate clinical research. It should be possible to detect and measure patterns of care and use the data to monitor improvements but there are methodological and data quality challenges. Driven by the desire to model the impact of a patient self-test blood count monitoring service in patients on chemotherapy, we aimed to (i) establish reproducible methods of process-mining electronic health records, (ii) use the outputs derived to define and quantify patient pathways during chemotherapy, and (iii) to gather robust data which is structured to be able to inform a cost-effectiveness decision model of home monitoring of neutropenic status during chemotherapy.
Methods
Electronic Health Records at a UK oncology centre were included if they had (i) a diagnosis of metastatic breast cancer and received adjuvant epirubicin and cyclosphosphamide chemotherapy or (ii) colorectal cancer and received palliative oxaliplatin and infusional 5fluorouracil chemotherapy, and (iii) were first diagnosed with cancer between January 2004 and February 2013. Software and a Markov model were developed, producing a schematic of patient pathways during chemotherapy.
Results
Significant variance from the assumed care pathway was evident from the data. Of the 535 patients with breast cancer and 420 with colorectal cancer there were 474 and 329 pathway variants respectively. Only 27 (5%) and 26 (6%) completed the planned six cycles of chemotherapy without having unplanned hospital contact. Over the six cycles, 169 (31.6%)
Introduction
Over the last 30 years, Western medicine has become increasingly systematised (1, 2) .
Drivers bringing this about include a call for improvements in quality, the desire to standardise care, a need to disseminate best practice, demands for cost containment coupled with rising demand and not least, patient safety (3) . An important tool in this regard has been clinical pathways that establish the expected standard of care and the processes and procedures that should be followed (4) . These pathways are becoming more evidence based (5, 6) , but such evidence is generally derived from carefully structured clinical trials rather than learning directly from routine clinical practice which can be very different.
Moreover, the majority of such clinical pathways are linear, relate to single conditions, and do not reflect real-life variations in individual patient genotype, phenotype, co-morbidities, environment and response to treatment. There are, therefore, good reasons to question whether perceived patterns of existing care are accurate and meaningful when used to plan and evaluate patient management.
With the trend towards integrated care and electronic health record (EHR) systems, a wealth of data on what actually happens to patients during their episodes of care are I (7) , with much of the focus being on applications of next generation sequencing genomics (8) .
Process mining is approach for discovering and analysing process models based on the very large event logs contained within information systems (9) and
there is a growing body of literature on process mining in healthcare (10). Our review of the process mining literature identified 37 peer reviewed papers using electronic health record (EHR) data to map pathways in oncology (11) . Challenges included the difficulty of capturing outpatient events (12) , the use of data collected for non-clinical purposes, missing data and clinically inaccurate time-stamps (13) . Our chemotherapy pathway mapping addressed these issues and is comprehensive and patient-centred, reporting most contacts the patient has with the hospital including in-and outpatient events, telephone contacts and pathology results. We use a novel iterative approach to addressing data quality through using clinical review to refine the model. We argue that mining true real-life clinical pathways of patients with cancer will facilitate the visualisation, quantification and improvement of such pathways.
The United Kingdom (UK) is in a strong position to address the issue of acquiring and applying lessons learned to improve complex patient pathways and outcomes due to the comprehensive nature of the National Health Service (NHS) model which extends across primary and secondary care with equity of access for all. The challenges were identified by the National Confidential Enquiry into Patient Outcome and Death (NCEPOD) in 2008, which reported that 42% of patients who died within thirty days of systemic anticancer therapy were admitted with a treatment related complication to a general medical ward, rather than to a ward with oncology-specific expertise (14). This identified problems at a high level with limited amount of detail. The NCEPOD and the National Chemotherapy Advisory Group highlighted the incompleteness of patient records, many of which were paper-based at the time, along with shortcomings of conventional real-life data collection (15). In the UK, EHRs are now commonly used in routine practice to collect comprehensive clinical data in all patients, at all points of care. We used a large and comprehensive EHR to study clinical pathways in patients with cancer receiving chemotherapy and their risk of developing neutropenic infections in order to get a more detailed understanding of neutropenic complications during chemotherapy.
We describe a methodology to extract detailed information on individual patient care pathways from Patient Pathway Manager (PPM), a mature, large and comprehensive EHR which has been in place for patients with cancer for over a decade in Leeds Teaching Hospitals NHS Trust (LTHT) (16, 17) . We studied patients with two common malignancies, breast and colorectal cancer, receiving two frequently used chemotherapy regimens;
adjuvant epirubicin and cyclophosphamide (EC90) and palliative oxaliplatin and modified de 
Materials & Methods

Patient Pathway Manager (PPM)
PPM is a mature EHR that is used to capture comprehensive clinical data on all patients PPM including surgery, cancer waiting times and multi-disciplinary team meetings ( Figure 1) .
The system has recently been extended to collate data on all patients whose care has been delivered at LTHT since 2000 and contains the records of more than 2.39 million patients. It is therefore one of the largest hospital EHRs in the UK. The PPM system now underpins the move away from paper records at LTHT and also provides the platform for the Leeds Care
Record, a common integrated digital care record used across the Leeds City Region for primary, secondary/tertiary care, social care, community care and mental health services.
Within PPM, each event is recorded with a patient identification and metadata, including date time stamp, enabling a historical pathway to be extracted for every patient.
Patient Selection Criteria
Patient records were included if the patient had (i) a diagnosis of breast cancer (ICD-10 C50) and received epirubicin and cyclophosphamide (EC90) chemotherapy as adjuvant treatment or (ii) a diagnosis of colorectal cancer (ICD-10 C18-C20) and received oxaliplatin and MDT -multi-disciplinary team, Chemocare -chemotherapy electronic prescribing system, PAS -patient administration system, Results server -LTHT software importing all patient investigation results from multiple disciplines, CWT -cancer waiting times, MOSAICradiation oncology software, ePRO -clinical information management system working with W hospital staff telephone patient, patient telephone inquiries patient rings hospital with a clinical inquiry.
Computing Resources
An information technology data analyst developed the data extraction and transformation software and developed the pathway model as described in the next section (Data mining software & Markov model development). Data in PPM is stored in a Microsoft SQL database and records for the two patient groups were extracted using C# with embedded SQL queries to create a secure Microsoft SQL database containing all relevant events. The software followed the extract, transform and load (ETL) design pattern (21) . Transformations to the data were coded to address completeness, quality, exclusion and aggregation issues and 
Data Mining Software & Markov Model Development
Data modelling followed a disciplined agile development process with eight iterations in total (22) . The first iteration started with a simplified model schematic of the patient pathway based on expert opinion (Figure 2); this was followed by the development of the initial data mining software that extracted only the Markov events in the patient pathway defined by the initial model. Rules used to transform clinical events into model states and a more detailed description of the whole process are described in Appendix B.
Software was developed to extract patient records from the main PPM dataset using database queries and segment these by regimen type and cycle number. A randomly generated integer was used to identify patients for pseudonymisation. Each patient was allocated to particular states in the model by applying a data mining process in two main stages. Firstly, events were extracted for each patient from PPM and transformed into a single table, ordered by date and time. Creation of the pathway of events for each patient is described in detail in Appendix B. Secondly, this pathway of events was matched to a pathway of states in the model described below (Figure 2) . A model state reflects a cluster of patient events happening within a small time span. In Figure 2 , chemotherapy delivery is the point at which the pathway starts, repeats and represents state S1 in the model. S1, patient presents and the chemotherapy goes ahead as normal. S2, patient attends hospital for chemotherapy but it is re-scheduled/delayed due to neutropenia. S3, patient is admitted acutely to hospital with problems unrelated to their cancer or treatment. S4, patient is admitted acutely to hospital with problems related to their cancer or treatment (not neutropenic). S5, Patient is admitted acutely to hospital with problems related to their cancer or treatment (neutropenic).
There were two main steps in each successive data model iteration ( Figure 3 ). First the model was redefined based on the results of data mining from the previous iteration, in order to account for complexity revealed by the data that was not previously foreseen; for example, a number of patients had blood test results present outside episodes of hospital care due to attendances at their GP. Secondly, there was further refinement of the data mining software based on the outcome of the model redefinition. This consisted of the addition of validation checks, to ensure that state transitions found in the data did not occur between states in the model that did not have a defined path between them. For example, it was initially indicated by the data that patients were still receiving chemotherapy treatment after they had died, which created state transitions in the model that were clearly invalid. This was caused by the pre-emptive booking of many treatments into the system while the patient was still alive which were not subsequently deleted.
The final model schematic of the patient pathway for a cycle of chemotherapy is shown in represent events that occur when the patient is due their next cycle of chemotherapy.
When patients experienced more than one state within a cycle of chemotherapy, they were prioritised by the most severe event (Table 1) , but counts were kept of the frequency of all health states. An uncomplicated case would be represented by a patient traversing through chemotherapy delivery (S1), followed by no contact (D1), then by patient review (R1) and back to chemotherapy delivery (S1 reasons other than neutropenia. C5, patient attends hospital for chemotherapy but it is rescheduled due to reasons other than neutropenia. Neutropenia is defined as a neutrophil count of < 1.5 x 10 9 /L. Bacteraemia is defined as any positive blood culture.
Results
Clinical Pathways
During The percentage of patients admitted to hospital over all the six cycles was higher than compared to phase III trials (23, 24 indicator of fever. There was also inconsistency over time in the chemotherapy regimen nomenclature used due to prescribing and recording systems changing, meaning that the two regimens studied were only referenced in the system by identical names in a subset of the total records. The remaining records were excluded due to uncertainty about whether the treatments were identical in drugs used, dosage and method of delivery. In light of the recent publication of the Caldicott report (25) , which this work pre-dates, we acknowledge there was no opt out process for patients from whom data was included in this analysis. This was a service evaluation process, with strict information governance procedures, where data was extracted, anonymised and analysed by aggregated pathways, not at an individual patient level.
Importantly, this pathway mapping provides additional data not apparent from national cancer datasets in the UK such as the National Cancer Waiting Times Monitoring Dataset (NCWTMD), Cancer Outcomes and Services Dataset, Systemic Anticancer Therapy Dataset and cancer registries (26) . Not all care elements are well represented in the national datasets such as suspected cancer diagnoses not referred by a general practitioner, care prior to a 2-week wait referral and care post referral to community palliative care teams. In addition to establishment of and checking adherence to guidelines, mapping real-life pathways gives a clear indication of current clinical practice, making it possible to identify unmet needs and process delays contributing to delayed targets, such as those mandated by the NCWTMD.
Specifically in the context of the research question that prompted this process mining initiative, the data has provided a more detailed picture of the issues around the risk of developing neutropenic sepsis, including how it is managed in routine practice. We selected the populations phenotypically using diagnosis and chemotherapy regimen combinations, but this can be narrowed further by selecting populations using parameters such as genotype and co-morbidity. We have demonstrated a method of organising clinical data into meaningful, quantified pathway models, which practically can be used to identify unmet need, model process improvements and inform health economic analyses. Focusing on neutropenic sepsis, the models of EC90 and OxMdG, can be used to determine where in the pathways home neutrophil monitoring will provide the greatest clinical and economic benefits for both patients and care providers.
As EHRs expand across care-provider boundaries, such as the Leeds Care Record, the ability to map such integrated pathways provides opportunity to measure health and healthcare in ways that have not been possible previously on large numbers of patients, including costs, clinical outcomes and societal impacts. In the UK NHS payments are based on Healthcare
Resource Group (HRG) codes, which assume an average payment for finished consultant episodes. The size and frequency of the variance in pathways may therefore adversely affect financial performance and the sustainability of an organisation. Basing commissioning contracts on idealised planned pathways is, therefore, prone to serious under estimation of true costs since many of the variant pathways have very high associated costs, such as admissions to intensive care (27) . 
Appendix B
Detailed description of the development of the datamining software and pathway models.
In early iterations of the software for this project, the full analysis took around 20 hours to run on a machine with an Intel Core I7 processor with 16GB of memory, but it was realised that patients could be processed independently of each other and the time to run was reduced to around 3 hours by using multithreading.
The warehousing process is done in three stages:
Stage 1
A cryptographically secure random integer for each patient is generated to be used as an anonymous identifier. This is stored in a separate database on a secure server within the Trust, and the patient is only referenced by their anonymous identifier in the warehouse database.
The relevant data for this study is stored in many different tables in the PPM database, for example, admission and discharge event data is stored in the admissions A copy of the regimens table from PPM is created, containing data from only the patients selected in the study, and with columns removed that are not relevant for this study.
Computed columns are added that do not exist in PPM; the regimen end date is calculated by taking the start date of the last cycle in the regimen and adding the cycle length. The diagnosis that the regimen is indicated for is inferred s that is closest to the regimen start date. This Table B1 : The rules used in stage 2 to transform raw events into model states. 
